Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice

Drug Safety

Volumn 28, Issue 1, 2005, Pages 67-80

  Chen, Yen Fu ^a,d   Avery, Anthony J ^a   Neil, Karen E ^a   Johnson, Christine ^b   Dewey, Michael E ^a   Stockley, Ivan H ^c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Beeston Primary Care Research Group   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMIODARONE; AMITRIPTYLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAHISTINE; BRONCHODILATING AGENT; CABERGOLINE; CINNARIZINE; CISAPRIDE; CLARITHROMYCIN; DOMPERIDONE; DOSULEPIN; ERYTHROMYCIN; EYE DROPS; IMIPRAMINE; LEVOBUNOLOL; LEVOTHYROXINE SODIUM; LOFEPRAMINE; NADOLOL; NITRATE; PHENELZINE; PROPRANOLOL; QUININE; SILDENAFIL; SOTALOL; SUMATRIPTAN; TERFENADINE; TIMOLOL; TRAMADOL; UNINDEXED DRUG;

ARTICLE; ASTHMA; BREATHING DISORDER; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER SYSTEM; DOCTOR PATIENT RELATION; DRUG CONTRAINDICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GENERAL PRACTICE; HEART ARRHYTHMIA; HUMAN; HYPOTHYROIDISM; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MEDICAL INFORMATION SYSTEM; MIGRAINE; PATIENT MONITORING; PHARMACIST; POPULATION RISK; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; RETROSPECTIVE STUDY; SIDE EFFECT; THORAX PAIN; UNITED KINGDOM;

DRUG INTERACTIONS; ENGLAND; FAMILY PRACTICE; HUMANS; INCIDENCE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; PHARMACEUTICAL PREPARATIONS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 12544252476     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200528010-00005     Document Type: Article

References (38)

1. Jankel CA, Speedie SM. Detecting drug interactions: a review of the literature. DICP 1990; 24: 982-9
2. Linnarsson R. Drug interactions in primary health care. Scand J Prim Health Care 1993; 11: 181-6
3. Sipilä J, Klaukka T, Martikainen J, et al. Occurrence of potentially harmful drug combinations among Finnish primary care patients. Int Pharm J 1995; 9: 104-7
4. Stevens RG, Balon D. Detection of hazardous drug/drug interactions in a community pharmacy and subsequent intervention. Int J Pharm Pract 1997; 5: 142-8
5. Rosholm JU, Bjerrum L, Halls J, et al. Polypharmacy and the risk of drug-drug interactions among Danish elderly. Dan Med Bull 1998; 45: 210-3
6. Halkin H, Katzir I, Kurman I, et al. Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin Pharmacol Ther 2001; 69: 260-5
7. Merlo J, Liedholm H, Lindblad U, et al. Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross sectional study. BMJ 2001; 323: 427-8
8. Evans JMM, Hayes JL, Lipworth BJ, et al. Potentially hazardous co-prescribing of β-adrenoceptor antagonists and agonists in the community. Br J Gen Pract 1996; 46: 423-5
9. Valuck RJ, Perlman JI, Anderson C, et al. Co-prescribing of medications used to treat obstructive lung disease, congestive heart failure and depression among users of topical beta blockers: estimates from three US Veterans Affairs Medical Centers. Pharmacoepidemiol Drug Saf 2001; 10: 511-6
10. Hanlon JT, Schmader KE, Boult C, et al. Use of inappropriate prescription drugs by older people. J Am Geriatr Soc 2002; 50: 26-34
11. Hartshorn EA. Significance and interpretation of drug interaction information. Drug Intell Clin Pharm 1970; 4: 173
12. Stockley IH. Drug interactions. 5th ed. London: Pharmaceutical Press, 1999
13. Hansten PD, Horn JR. Hansten and Horn's managing clinically important drug interactions. Vancouver (WA): Applied Therapeutics Inc, 1998
14. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45
15. Leape LL, Bates DW, Cullen DJ, et al. Systems analysis of adverse drug events. JAMA 1995; 274: 35-43
16. Joint Formulary Committee. British National Formulary 39. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2000
17. Newman CM, Price A, Davies DW, et al. Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy. Heart 1998; 79: 121-7
18. Loh K-C. Amiodarone-induced thyroid disorders: a clinical review. Postgrad Med J 2000; 76: 133-40
19. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. JAMA 2000; 284: 3036-9
20. Jones JK, Fife D, Curkendall S, et al. Coprescribing and codispensing of cisapride and contraindicated drugs. JAMA 2001; 286: 1607-9
21. Weatherby LB, Walker AM, Fife D, et al. Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of 'Dear Doctor' letters. Pharmacoepidemiol Drug Saf 2001; 10: 211-8
22. Raschetti R, Maggini M, Da Cas R, et al. Time trends in the coprescribing of cisapride and contraindicated drugs in Umbria, Italy. JAMA 2001; 285: 1840-1
23. Jones FLJ, Ekberg NL. Exacerbation of obstructive airway disease by timolol [letter]. JAMA 1980; 244: 2730
24. Schoene RB, Martin TR, Charan NB, et al. Timolol-induced bronchospasm in asthmatic bronchitis. JAMA 1981; 245: 1460-1
25. Fraunfelder FT, Barker AF. Respiratory effects of timolol [letter]. N Engl J Med 1984; 311: 1441
26. Schoene RB, Abuan T, Ward RL, et al. Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis. Am J Ophthalmol 1984; 97: 86-92
27. Diggory P, Heyworth P, Chau G, et al. Unsuspected bronchospasm in association with topical timolol -a common problem in elderly people: can we easily identify those affected and do cardioselective agents lead to improvement? Age Ageing 1994; 23: 17-21
28. Diggory P, Cassels-Brown A, Vail A, et al. Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents. Lancet 1995; 345: 1604-6
29. Good CB. Topical beta-blockers in patients with co-existing conditions: is this a cause for concern? [editorial]. Pharmacoepidemiol Drug Saf 2001; 10: 509-10
30. Mageean RJ. Study of 'discharge communications' from hospital. BMJ 1986; 293: 1283-4
31. Penney TM. Delayed communication between hospitals and general practitioners: where does the problem lie? BMJ 1988; 297: 28-9
32. Williams EI, Fitton F. General practitioner response to elderly patients discharged from hospital. BMJ 1990; 300: 159-61
33. Coleman A, Ricketts L, Teal S, et al. An audit of hospital discharge and outpatient information from a primary care perspective. J Soc Adm Pharm 2001; 18: 226-31
34. Zermansky AG. Who controls repeats? Br J Gen Pract 1996; 46: 643-7
35. Bradley CP, Fraser A. Repeat prescribing. Br J Gen Pract 1997; 47: 255-6
36. Magnus D, Rodgers S, Avery AJ. GPs' views on computerised drug interaction alerts: questionnaire survey. J Clin Pharm Ther 2002; 27: 377-82
37. Hazlet TK, Lee TA, Hansten PD, et al. Performance of community pharmacy drug interaction software. J Am Pharm Assoc 2001; 41: 200-4
38. Pringle M, Ward P, Chilvers C. Assessment of the completeness and accuracy of computer medical records in four practices committed to recording data on computer. Br J Gen Pract 1995; 45: 537-41